1. Home
  2. ACFN vs GRML Comparison

ACFN vs GRML Comparison

Compare ACFN & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ACFN

Acorn Energy Inc.

SELL

Current Price

$18.39

Market Cap

46.8M

ML Signal

SELL

GRML

Greenland Mines Ltd. Common Stock

N/A

Current Price

$0.40

Market Cap

41.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ACFN
GRML
Founded
1986
N/A
Country
United States
United States
Employees
27
5
Industry
Military/Government/Technical
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
46.8M
41.9M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
ACFN
GRML
Price
$18.39
$0.40
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
12.5K
3.0M
Earning Date
05-07-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$6.63
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.42
$0.27
52 Week High
$33.00
$0.45

Technical Indicators

Market Signals
Indicator
ACFN
GRML
Relative Strength Index (RSI) 49.43 52.14
Support Level $18.16 $0.31
Resistance Level $19.87 $0.43
Average True Range (ATR) 0.99 0.06
MACD 0.09 0.01
Stochastic Oscillator 63.27 68.53

Price Performance

Historical Comparison
ACFN
GRML

About ACFN Acorn Energy Inc.

Acorn Energy Inc is a holding company that focuses on technology-driven solutions for energy infrastructure asset management. The company operates through two segments namely, the PG segment and the CP segment. PG segment provides wireless remote monitoring and control systems and services for critical assets as well as Internet of Things applications which account for the majority of the revenue. CP segment is engaged in providing remote monitoring of cathodic protection systems on gas pipelines for gas utilities and pipeline companies.

About GRML Greenland Mines Ltd. Common Stock

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.

Share on Social Networks: